- Medication and Pregnancy KB

Study	Type of data	Exposure measurement	Outcome assessment	Adjustment
Ephross (Naratriptan versus Sumatriptan), 2014	prospective cohort	Shortly after the expected date of birth, registry personnel contacted the enrolling health care provider to obtain information focused on the use of sumatriptan, naratriptan, and/or the sumatriptan/naproxen sodium combination product and other headache medications during pregnancy.	Shortly after the expected date of birth, registry personnel contacted the enrolling health care provider to obtain information focused on the outcome of pregnancy. All defect reports were reviewed by two clinicians: a pediatrician and an obstetrician-gynecologist.	None
Källén (control exposed to ergots), 2011	population based cohort propective	Pregnant women who attend antenatal clinics in Sweden (which the vast majority do) are interviewed by a midwife and asked about drugs used since the pregnancy started. This interview is usually made before the end of the first trimester (usually between weeks 10 and 12 of pregnancy).	The outcomes were ascertained from multiple sources: the paediatric form of the Medical Birth Register, the Register of Birth Defects and the Patient Register.	No adjustment for this control group.
Källén (control unexposed, disease free), 2011	population based cohort propective	Pregnant women who attend antenatal clinics in Sweden (which the vast majority do) are interviewed by a midwife and asked about drugs used since the pregnancy started. This interview is usually made before the end of the first trimester (usually between weeks 10 and 12 of pregnancy).	The outcomes were ascertained from multiple sources: the paediatric form of the Medical Birth Register, the Register of Birth Defects and the Patient Register.	No adjustment for this group of exposure.
Spielmann (Control mainly exposed other treatments, sick), 2017	prospective cohort	All data are recorded using structured questionnaires via phone interview and/or as a written form.	Structured questionnaire administered via phone interview and/or as a written form, notably on gestational age at birth, weight, length, head circumference, Apgar score, umbilical artery pH, birth defects, postnatal disorders, pregnancy loss. Medical reports requested in cases of birth defects.	No adjustment for this group of exposure.
Spielmann (Control unexposed, disease free), 2017	prospective cohort	All data are recorded using structured questionnaires via phone interview and/or as a written form.	Structured questionnaire administered via phone interview and/or as a written form, notably on gestational age at birth, weight, length, head circumference, Apgar score, umbilical artery pH, birth defects, postnatal disorders, pregnancy loss. Medical reports requested in cases of birth defects.	No adjustment for this group of exposure.
Yusuf (Control exposed to Sumatriptan), 2018	retrospective cohort (claims database)	Administrative claims data contained in the Truven Health Marketscan Com- mercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits Databases.	Administrative claims data contained in the Truven Health Marketscan Com- mercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits Databases.	None

master protocol